Breaking Finance News

Panmure Gordon disclosed Vernalis PLC (LON:VER), supporting its price target at 76.00GBX earlier today

Indicating as possible upside of 0.71%, Panmure Gordon hold steady the target price of Vernalis PLC (LON:VER) at 76.00GBX

Previously on Tuesday September 06, 2016, Canaccord Genuity released a statement about Vernalis PLC (LON:VER) held steady the target price at 84.00GBX. At the time, this indicated a possible upside of 0.91%.

Just yesterday Vernalis PLC (LON:VER) traded 1.69% higher at 44.38GBX. Vernalis PLC’s 50-day moving average is 43.89GBX and its 200-day moving average is 46.31GBX. The last stock price is down -2.83% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 32,818 shares of VER traded hands, down from an average trading volume of 304,548

Performance Chart

Vernalis PLC (LON:VER)

With a total market value of 0 GBX, Vernalis PLC has with a one year low of 31.00GBX and a one year high of 84.75GBX .

A total of 5 equity analysts have released a research note on VER. Two equity analysts rating the company a strong buy, two equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 83.60GBX.

More About Vernalis PLC (LON:VER)

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.